EA201100902A1 - Новый способ получения рнк-вируса - Google Patents

Новый способ получения рнк-вируса

Info

Publication number
EA201100902A1
EA201100902A1 EA201100902A EA201100902A EA201100902A1 EA 201100902 A1 EA201100902 A1 EA 201100902A1 EA 201100902 A EA201100902 A EA 201100902A EA 201100902 A EA201100902 A EA 201100902A EA 201100902 A1 EA201100902 A1 EA 201100902A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new method
rna virus
obtaining rna
obtaining
provides
Prior art date
Application number
EA201100902A
Other languages
English (en)
Other versions
EA018564B1 (ru
Inventor
Томас Мустер
Андрей Егоров
Маркус Волшек
Original Assignee
Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг filed Critical Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг
Publication of EA201100902A1 publication Critical patent/EA201100902A1/ru
Publication of EA018564B1 publication Critical patent/EA018564B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение обеспечивает способ получения вирусов с сегментированным негативным РНК-геномом с помощью линейных экспрессирующих конструктов в присутствии вируса-помощника.
EA201100902A 2008-12-03 2009-12-03 Новый способ получения рнк-вируса EA018564B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11961808P 2008-12-03 2008-12-03
EP09155594A EP2233568A1 (en) 2009-03-19 2009-03-19 Novel method for generation of RNA virus
PCT/EP2009/066358 WO2010063804A1 (en) 2008-12-03 2009-12-03 Novel method for generation of rna virus

Publications (2)

Publication Number Publication Date
EA201100902A1 true EA201100902A1 (ru) 2011-12-30
EA018564B1 EA018564B1 (ru) 2013-08-30

Family

ID=40785339

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100902A EA018564B1 (ru) 2008-12-03 2009-12-03 Новый способ получения рнк-вируса

Country Status (8)

Country Link
US (2) US8741301B2 (ru)
EP (2) EP2233568A1 (ru)
JP (1) JP2012510283A (ru)
KR (1) KR20110101137A (ru)
CN (1) CN102239250A (ru)
CA (1) CA2745259A1 (ru)
EA (1) EA018564B1 (ru)
WO (1) WO2010063804A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2459722B1 (en) * 2009-07-31 2017-09-06 Seqirus UK Limited Reverse genetics systems
WO2011151470A2 (en) * 2010-06-02 2011-12-08 Avir Green Hills Biotechnology Research Development Trade Ag Novel method for generation of rna virus
WO2013103808A1 (en) * 2012-01-05 2013-07-11 Viracine Therapeutics Corporation Expression of negative sense rna viruses and double-stranded rna viruses, and uses thereof
US12178869B2 (en) 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
RU2020132280A (ru) 2018-03-08 2022-04-11 Кодадженикс Инк. Аттенуированные флавивирусы
CN113853215B (zh) 2019-01-24 2025-07-18 蓝天免疫疗法有限责任公司 高生长流感病毒
CN111635960B (zh) * 2020-05-06 2023-06-27 温州医科大学附属眼视光医院 用于稳态速效检测新型冠状病毒的保护序列、引物、探针、组合物、试剂盒及应用和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
ES2301241T3 (es) 1998-06-12 2008-06-16 Mount Sinai School Of Medicine Of The City University Of New York Virus de influenza a atenuados, y composiciones inmunogenicas y formulaciones de vacunas que los contienen.
US6280977B1 (en) 1999-03-24 2001-08-28 Gene Therapy Systems Method for generating transcriptionally active DNA fragments
EP1185615B1 (en) 1999-04-06 2007-08-01 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
DE122007000070I1 (de) 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
PL205955B1 (pl) * 2000-04-28 2010-06-30 St Jude Childrens Res Hospital Układ oparty na minimalnej liczbie plazmidów do wytwarzania infekcyjnych wirusów RNA o ujemnej nici, komórka gospodarza zawierająca taki układ, sposób wytwarzania wiriona wirusa RNA o ujemnej nici, sposób wytwarzania atenuowanego wirusa RNA o ujemnej nici, sposób wytwarzania zakaźnego wirusa o ujemnej nici do stosowania w szczepionkach i zastosowanie układu opartego na minimalnej liczbie plazmidów
AU2005287395A1 (en) * 2004-07-02 2006-03-30 Henry L. Niman Copy choice recombination and uses thereof
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles

Also Published As

Publication number Publication date
US20100184191A1 (en) 2010-07-22
US8741301B2 (en) 2014-06-03
EP2233568A1 (en) 2010-09-29
EP2370567A1 (en) 2011-10-05
CA2745259A1 (en) 2010-06-10
EA018564B1 (ru) 2013-08-30
WO2010063804A1 (en) 2010-06-10
US8778357B2 (en) 2014-07-15
KR20110101137A (ko) 2011-09-15
CN102239250A (zh) 2011-11-09
US20110250587A1 (en) 2011-10-13
JP2012510283A (ja) 2012-05-10

Similar Documents

Publication Publication Date Title
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1121159T1 (el) Μη-ενσωματουμενοι λεντiϊικοι φορεις
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
TR201815882T4 (tr) Tal efektörü aracılı dna modifikasyonu.
EA201001045A1 (ru) Модифицированный вирус гриппа
DK2242752T3 (da) Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer
CY1119173T1 (el) Νεα μορια αναστολεα jnk
BRPI0921651A2 (pt) Método para produzir adenovírus recombinante, e partículas virais, e, biorreator
ITRM20100277A1 (it) Carcassa di turbina.
ATE555109T1 (de) Hepatitis-c-virus-hemmer
TR201910311T4 (tr) L-metiyonin öncüsü üreten mikroorganizma ve mikroorganizma kullanarak L-metiyonin öncüsü üretme yöntemi.
CL2011002082A1 (es) Composicion farmaceutica que comprende un inhibidor de nucleosido polimerasa y un inhibidor de proteasa macrociclica; proceso para preparar dicha composicion farmaceutica; metodo para tratar o mejorar una infeccion con virus de la hepatitis c, fibrosis hepatica y alteracion de la funcion hepatica.
WO2010132604A3 (en) Neutralizing molecules to influenza viruses
EA201071086A1 (ru) Усовершенствованный способ получения вакцинных антигенов вируса гриппа
MX2009006469A (es) Metodo de duplicacion del virus de la influenza en cultivo.
EP2552547A4 (en) MATERIALS AND METHODS RELATED TO THE MODULATION OF INCORPORATION AND GENERAL STABILITY BY ME-155
BRPI0916967A2 (pt) produção de silício através da reação de óxido de silício e carbureto de silício, opcionalmente na presença de uma segunda fonte de carbono
EA201270577A1 (ru) Усовершенствованные способы обратной генетики для спасения вирусов
IT1395239B1 (it) Procedimento per la produzione di componenti strutturali induriti con procedimenti di riscaldamento di svariati tipi.
EA201070092A1 (ru) Адаптация вируса бешенства штамма pitman moore к первичной клеточной культуре фибробластов куриных эмбрионов
EP2366024A4 (en) COMPOSITIONS, METHODS AND USE FOR INTRODUCING VIRUS GROWTH
EA201300916A1 (ru) Способ получения prrsv в коммерческом масштабе
EP2239227A4 (en) MEDIUM FOR SYNTHESIS OF CARBON NANOTUBES
EA201201620A1 (ru) Способ получения рнк-вируса

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU